MADIT-II: clinical implications

Card Electrophysiol Rev. 2002 Dec;6(4):463-5. doi: 10.1023/a:1021104929368.

Abstract

The MADIT-II trial showed that in patients with a prior myocardial infarction and ejection fraction </=0.30, prophylactic implantation of a defibrillator improves survival with a 31% reduction in mortality during an average follow-up of 20 months. Electrophysiologic inducibility was positive in 36% of patients at the time of ICD implantation. Inducibility was associated with increased ICD utilization for ventricular tachycardia during long-term follow-up, and decreased utilization for ventricular fibrillation. These preliminary findings raise questions about the clinical usefulness of electrophysiologic testing as a risk stratifier in patients with advanced left ventricular dysfunction.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Anti-Arrhythmia Agents / therapeutic use*
  • Death, Sudden, Cardiac / prevention & control*
  • Defibrillators, Implantable*
  • Electrocardiography
  • Female
  • Follow-Up Studies
  • Heart Function Tests
  • Hemodynamics / physiology
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / complications*
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / mortality
  • Probability
  • Proportional Hazards Models
  • Risk Assessment
  • Risk Factors
  • Severity of Illness Index
  • Survival Analysis
  • Tachycardia, Ventricular / diagnosis
  • Tachycardia, Ventricular / etiology
  • Tachycardia, Ventricular / mortality
  • Tachycardia, Ventricular / therapy*
  • Treatment Outcome
  • Ventricular Dysfunction, Left / complications*
  • Ventricular Dysfunction, Left / diagnosis
  • Ventricular Dysfunction, Left / mortality

Substances

  • Anti-Arrhythmia Agents